Founded in 2004 in Uppsala, Sweden, Olink® revolutionized proteomics with its Proximity Extension Assay (PEA) technology, enabling highly specific and sensitive protein analysis. Now a global leader, Olink® collaborates with academia, biotech, and pharma to drive breakthroughs in biomarker discovery, disease research, and precision medicine.
With integrated NPX Signature software on the Signature Q100 and advanced Olink Insight analysis for NGS platforms, Olink streamlines protein data processing, delivering precise, high-quality results directly from the instrument. This automation boosts efficiency, accelerates workflows, and reduces turnaround time for biomarker discovery, clinical studies, and translational research.
Proteomic shifts reveal aging, health insights.
Biomarkers improve diagnosis, treatment, risk assessment.
Protein analysis uncovers autoimmune disease mechanisms.
Understand and monitor neurodegenerative disease progression.
Understand and monitor neurodegenerative disease progression.
With unmatched sensitivity, specificity, and scalability, Olink’s platforms empower researchers to decode complex biology with minimal sample input. Whether you need a benchtop solution like Signature Q100 or high-throughput NGS-based panels like Olink Explore, our portfolio offers flexible, proven tools to match your proteomics needs—from discovery to clinical translation.
Olink Signature Q100: High-sensitivity platform for precise protein biomarker detection.
OlinkPanels enable precise, scalable protein biomarker discovery globally.
Olink Insight and Analyze streamline data interpretation for impactful discoveries.
PEA technology and unmatched protein data quality to drive discovery with confidence
Integrates proteomics and genetics for drug discovery
Enables smooth biomarker-to-clinic transition
Deep insights to accelerate drug development
Protein data powers precision medicine decisions